Number and Characteristics of Patients Receiving Opioid Treatment Programs (OTPs) in the US

"MAT [Medication Assisted Opioid Therapy] includes the use of methadone and buprenorphine for the treatment of opioid addiction or dependence, and the use of the extended-release injectable naltrexone (Vivitrol®) (injectable naltrexone) for relapse prevention in opioid addiction. Methadone is available only at OTP facilities that are certified by SAMHSA’s Center for Substance Abuse Treatment. Buprenorphine may be prescribed by physicians who have received DATA 2000 specific training and received a waiver to prescribe the medication for treatment of opioid addiction; some of these physicians are affiliated with facilities26 (either OTPs or other). All physicians or approved medical personnel can prescribe extended-release injectable naltrexone (Vivitrol®).27
"• Of the total 1,305,647 clients in treatment, 378,791 (29 percent) received MAT in OTP facilities.
"• There were 356,843 clients receiving methadone in OTP facilities.
"• • Of the clients receiving methadone, 213,421 clients (60 percent) were provided treatment at private for-profit OTPs and 121,499 clients (34 percent) were provided treatment at private non-profit OTPs.
"• There were 21,236 clients receiving buprenorphine in OTP facilities and 54,488 clients receiving buprenorphine in non-OTP facilities.
"•• Of the clients receiving buprenorphine in OTPs, 11,016 clients (52 percent) were provided treatment at private for-profit facilities and 6,850 clients (32 percent) were provided treatment at private non-profit OTPs.
"•• Of the clients receiving buprenorphine in non-OTP facilities, 25,270 clients (46 percent) were provided treatment at private for-profit facilities and 22,299 clients (41 percent) were provided treatment at private non-profit organizations.
"• There were 712 clients receiving extended-release injectable naltrexone (Vivitrol®) in OTP facilities and 6,323 clients receiving extended-release injectable naltrexone (Vivitrol®) in non-OTP facilities.
"•• Of the clients receiving extended-release injectable naltrexone (Vivitrol®) in OTPs, 411 clients (58 percent) were provided treatment at private non-profit facilities and 82 clients (12 percent) were provided treatment at private for-profit OTPs.
"•• Of the clients receiving extended-release injectable naltrexone (Vivitrol®) in non-OTP facilities, 2,935 clients (46 percent) were provided treatment at private non-profit facilities and 2,634 clients (42 percent) were provided treatment at private for-profit organizations.

Source: 

Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS): 2015. Data on Substance Abuse Treatment Facilities. BHSIS Series S-88, HHS Publication No. (SMA) 17-5031. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2017, pp. 36-37.
https://www.samhsa.gov/data/su...
https://www.samhsa.gov/data/si...

Region: 
Substance: